Abstract
Chronic kidney disease (CKD) affects 12% of the population worldwide,1 is a major cause of morbidity and mortality, and consumes health-care resources.2 A primary therapeutic goal for the treatment of CKD is prevention of kidney failure and cardiovascular disease (CVD).3,4 Healthy lifestyle behaviours, blood pressure (BP) lowering, maintaining glucose control (in people with diabetes), and renin and angiotensin aldosterone system (RAAS) blockers have been the cornerstone of therapy for patients with CKD since the late 1990s.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call